Thus, the SHN3-targeting gene therapy approach taken here is also anticipated to be complimentary to either established osteoanabolic or anti-resorptive therapeutics or to emerging therapeutic approaches that specifically target the molecular pathogenesis of OI, such as anti TGF-β antibodies.5,12. Here, TGFB1 is linked to osteogenesis imperfecta.